Valuation: Intra-Cellular Therapies, Inc.

Market Cap 1.4TCr 1.23TCr 1.13TCr 1.05TCr 1.97TCr 1,34700Cr 2.01TCr 14TCr 5.3TCr 66TCr 5.27TCr 5.15TCr 2,27100Cr P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 1.3TCr 1.14TCr 1.05TCr 973.07Cr 1.83TCr 1,25200Cr 1.87TCr 13TCr 4.93TCr 61TCr 4.9TCr 4.79TCr 2,11100Cr EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Compliance Officer 64 02/07/2019
Chief Tech/Sci/R&D Officer - 01/04/2022
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
02/25/02Issuer sale

Executive Vice President & CFO

75,024 0.0706%
02/25/02Issuer sale

Director

2,42,551 0.2281%
02/25/02Issuer sale

Chief Executive Officer

20,48,863 1.9269%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+107.60% 1.4TCr
+1.27%+0.12%+21.12%-8.02% 6.68TCr
+1.38%-5.23%+38.08%+194.04% 5.06TCr
+1.10%+38.30%+38.30%+38.30% 4.25TCr
-0.98%-1.79%-49.61%-53.35% 4.12TCr
+2.04%-2.88%+52.62%-30.10% 2.83TCr
-0.93%-8.75%+112.84%-45.18% 2.68TCr
-0.30%-2.04%+68.31%+88.06% 2.3TCr
+7.77%+11.30%+18.35%+199.08% 2TCr
-1.88%+5.49%+75.94%+157.90% 1.65TCr
Average +0.94%-2.14%+37.60%+64.83% 3.3TCr
Weighted average by Cap. +0.93%-2.85%+32.23%+50.90%

Financials

2023 2024
Net sales 46Cr 41Cr 38Cr 35Cr 65Cr 4.46TCr 66Cr 447.38Cr 175.53Cr 2.18TCr 174.43Cr 170.57Cr 7.52TCr 68Cr 59Cr 55Cr 51Cr 96Cr 6.54TCr 97Cr 655.94Cr 257.36Cr 3.2TCr 255.74Cr 250.09Cr 11TCr
Net income -14Cr -12Cr -11Cr -10Cr -20Cr -1.34TCr -20Cr -134.56Cr -53Cr -656.95Cr -52Cr -51Cr -2.26TCr -7.47Cr -6.53Cr -6.03Cr -5.57Cr -10Cr -717.29Cr -11Cr -72Cr -28Cr -351.23Cr -28Cr -27Cr -1.21TCr
Net Debt -48Cr -42Cr -39Cr -36Cr -68Cr -4.62TCr -69Cr -463.4Cr -181.81Cr -2.26TCr -180.67Cr -176.68Cr -7.79TCr -98Cr -86Cr -80Cr -73Cr -138.32Cr -9.45TCr -140.82Cr -948.07Cr -371.97Cr -4.63TCr -369.64Cr -361.47Cr -16TCr
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock